Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluticasone Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 12/20 | 0.67 |
| ▸ | PGR | P06401 | 6/20 | 0.67 |
| ▸ | AR | P10275 | 5/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluticasone Propionate SCHEMBL4281973 | 0.88 | NR3C1 (0.70) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluocinolone Acetonide SCHEMBL2251974 | 0.87 | NR3C1 (0.82) | NR3C1PGRARCYP3A4NR1I2 | |
| Flunisolide SCHEMBL221433 | 0.85 | PGR (0.73) | NR3C1PGRARCYP3A4NR1I2 | |
| Fluticasone Propionate SCHEMBL6809924 | 0.84 | NR3C1 (0.61) | NR3C1PGRARCYP3A4ADORA3 | |
| Halobetasol Propionate SCHEMBL4288075 | 0.84 | PGR (0.63) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL28834034 | 0.83 | NR3C1 (0.70) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL9363101 | 0.82 | NR3C1 (0.97) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL9363108 | 0.82 | NR3C1 (0.97) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL14343427 | 0.82 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL416179 | 0.82 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177574-A1 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20200131265-A1 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
| US-20190218288-A1 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2019-07-18 | — | — | US | disclosed |
| US-10100116-B2 | FcγRIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| EP-2029173-B1 | FC RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS INC (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-1534335-B9 | FCGAMMARIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150344574-A1 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344575-A1 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| EP-1534335-B2 | FCGAMMARIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS INC (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20150023964-A1 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| WO-2005115452-A9 | FCϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS INC (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060013810-A1 | Humanized FcgammaRIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005115452-A2 | FCϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050260213-A1 | Fcgamma-RIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005110474-A2 | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050215767-A1 | Fcgamma riib specific antibodies and methods of use thereof | MACROGENICS INC. | 2005-09-29 | — | — | US | disclosed |
| EP-1534335-A2 | FCGAMMARIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005018669-A1 | FCϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040185045-A1 | FcgammaRIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004016750-A2 | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |